Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C45H63N13O12S2 |
Molecular Weight | 1042.1956 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]2CSSC[C@H](N)C(=O)N[C@@H](CC3=CC=C(O)C=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N2)C(=O)NCC(N)=O
InChI
InChIKey=MUNMIGOEDGHVLE-LGYYRGKSSA-N
InChI=1S/C45H63N13O12S2/c46-16-4-8-28(39(64)51-21-37(50)62)53-44(69)34-9-5-17-58(34)45(70)33-23-72-71-22-27(47)38(63)54-30(19-25-10-12-26(59)13-11-25)42(67)55-31(18-24-6-2-1-3-7-24)41(66)52-29(14-15-35(48)60)40(65)56-32(20-36(49)61)43(68)57-33/h1-3,6-7,10-13,27-34,59H,4-5,8-9,14-23,46-47H2,(H2,48,60)(H2,49,61)(H2,50,62)(H,51,64)(H,52,66)(H,53,69)(H,54,63)(H,55,67)(H,56,65)(H,57,68)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/9587717Curator's Comment: Description was created based on several sources, including https://gp2u.com.au/static/pdf/P/POR-8_FERRING-PI.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9587717
Curator's Comment: Description was created based on several sources, including https://gp2u.com.au/static/pdf/P/POR-8_FERRING-PI.pdf
Ornipressin (ornithine-8-vasopressin, POR-8), is a synthetic vasopressin analogue. Ornipressin produces vasoconstriction via vasopressin V1A receptor-mediated vascular smooth muscle cell contraction. Ornipressin is used to control
bleeding in surgical practice. It was introduced in 1971, and approved for use in Germany, Switzerland, New Zealand and Australia.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1889 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21688787 |
9.16 null [pEC50] | ||
Target ID: CHEMBL1921 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21688787 |
8.12 null [pEC50] | ||
Target ID: CHEMBL1790 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21688787 |
9.35 null [pEC50] | ||
Target ID: CHEMBL2049 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21688787 |
7.15 null [pEC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9587717 |
Preventing | POR-8 Approved UsePOR-8 FERRING® (Ornipressin) is used to help control bleeding. It narrows blood vessels at the site of an operation.
Indications
Local administration: to induce ischaemia and haemostasis at the site of an operation in various types of surgery where bleeding is a problem.
Plastic Surgery: Hair transplants, meloplasty, otoplasty, skin grafts, resection of tumours etc.
Obstetrics/Gynaecology: Vaginal repair, vaginal hysterectomy, cone biopsy of cervix, episiotomy, myomectomy.
ENT Surgery: Tonsillectomy, submucous resection of septum, myringoplasty etc.
Other types of surgery: Neurosurgery, orofacial surgery, surgery of head and neck, abdominal and rectal surgery, care of burns (excision of eschar). |
Sample Use Guides
POR-8 FERRING® (Ornipressin) should be diluted before use. Usually 5 I.U. (1 ampoule) is diluted in 30 mL of physiological saline. No data are available on the compatibility or stability of POR-8 FERRING® when mixed with local anaesthetic solution. The diluted solution is administered by regional infiltration at the operation site.
The maximum permitted total dose for tissue infiltration is 5 I.U., due to the possibility of systemic absorption.
For gynaecological surgery and laparotomies, more dilute solutions, e.g. 5 I.U. in 50 or 60 mL physiological saline are used.
For ENT surgery, somewhat more concentrated solutions, 5 I.U. in 20 mL physiological saline may be required.
Extemporaneous dilutions of POR-8 FERRING® should be used on the day on which they are prepared.
Route of Administration:
Topical
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
H01BA05
Created by
admin on Mon Mar 31 18:50:02 GMT 2025 , Edited by admin on Mon Mar 31 18:50:02 GMT 2025
|
||
|
NCI_THESAURUS |
C80212
Created by
admin on Mon Mar 31 18:50:02 GMT 2025 , Edited by admin on Mon Mar 31 18:50:02 GMT 2025
|
||
|
WHO-VATC |
QH01BA05
Created by
admin on Mon Mar 31 18:50:02 GMT 2025 , Edited by admin on Mon Mar 31 18:50:02 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
14257660
Created by
admin on Mon Mar 31 18:50:02 GMT 2025 , Edited by admin on Mon Mar 31 18:50:02 GMT 2025
|
PRIMARY | |||
|
222-253-8
Created by
admin on Mon Mar 31 18:50:02 GMT 2025 , Edited by admin on Mon Mar 31 18:50:02 GMT 2025
|
PRIMARY | |||
|
m8238
Created by
admin on Mon Mar 31 18:50:02 GMT 2025 , Edited by admin on Mon Mar 31 18:50:02 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID101021593
Created by
admin on Mon Mar 31 18:50:02 GMT 2025 , Edited by admin on Mon Mar 31 18:50:02 GMT 2025
|
PRIMARY | |||
|
ORNIPRESSIN
Created by
admin on Mon Mar 31 18:50:02 GMT 2025 , Edited by admin on Mon Mar 31 18:50:02 GMT 2025
|
PRIMARY | |||
|
4679
Created by
admin on Mon Mar 31 18:50:02 GMT 2025 , Edited by admin on Mon Mar 31 18:50:02 GMT 2025
|
PRIMARY | |||
|
D009951
Created by
admin on Mon Mar 31 18:50:02 GMT 2025 , Edited by admin on Mon Mar 31 18:50:02 GMT 2025
|
PRIMARY | |||
|
C87774
Created by
admin on Mon Mar 31 18:50:02 GMT 2025 , Edited by admin on Mon Mar 31 18:50:02 GMT 2025
|
PRIMARY | |||
|
1KTH6N080W
Created by
admin on Mon Mar 31 18:50:02 GMT 2025 , Edited by admin on Mon Mar 31 18:50:02 GMT 2025
|
PRIMARY | |||
|
100000083348
Created by
admin on Mon Mar 31 18:50:02 GMT 2025 , Edited by admin on Mon Mar 31 18:50:02 GMT 2025
|
PRIMARY | |||
|
3397-23-7
Created by
admin on Mon Mar 31 18:50:02 GMT 2025 , Edited by admin on Mon Mar 31 18:50:02 GMT 2025
|
PRIMARY | |||
|
DB13464
Created by
admin on Mon Mar 31 18:50:02 GMT 2025 , Edited by admin on Mon Mar 31 18:50:02 GMT 2025
|
PRIMARY | |||
|
SUB09465MIG
Created by
admin on Mon Mar 31 18:50:02 GMT 2025 , Edited by admin on Mon Mar 31 18:50:02 GMT 2025
|
PRIMARY | |||
|
CHEMBL1819440
Created by
admin on Mon Mar 31 18:50:02 GMT 2025 , Edited by admin on Mon Mar 31 18:50:02 GMT 2025
|
PRIMARY | |||
|
2544
Created by
admin on Mon Mar 31 18:50:02 GMT 2025 , Edited by admin on Mon Mar 31 18:50:02 GMT 2025
|
PRIMARY | |||
|
7703
Created by
admin on Mon Mar 31 18:50:02 GMT 2025 , Edited by admin on Mon Mar 31 18:50:02 GMT 2025
|
PRIMARY | RxNorm |
ACTIVE MOIETY